PRADO: Phase II Trial of Response-Directed Surgery and Adjuvant Therapy Following Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma

CheckMate 915: association of ctDNA and other translational factors at baseline with RFS in patients with stage IIIB-D/IV melanoma receiving adjuvant immunotherapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Phase II SWOG S1801 study: neoadjuvant vs adjuvant treatment with pembrolizumab in patients with resectable stage III-IV melanoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Additional response results from RELATIVITY-047 evaluating the addition of relatlimab to nivolumab vs nivolumab in advanced melanoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022